Alimera Sciences Reports Second Quarter 2024 Results

Rhea-AI Summary

Alimera Sciences reported strong Q2 2024 results with net revenue up 54% to $27 million compared to Q2 2023. Key highlights include:

- U.S. net revenue increased 48% to $17.6 million
- International net revenue grew 65% to $9.4 million
- Global end user demand up 6% to 3,821 units
- Net loss improved to $(3.3) million from $(10.7) million in Q2 2023
- Adjusted EBITDA of $6.7 million vs. $0.9 million in Q2 2023

The company recently announced a definitive merger agreement with ANI Pharmaceuticals, valuing Alimera's equity at approximately $320 million in upfront consideration. The transaction is expected to close later this year.

Positive

• Net revenue increased 54% year-over-year to $27 million
• U.S. net revenue grew 48% to $17.6 million
• International net revenue rose 65% to $9.4 million
• Global end user demand increased 6% to 3,821 units
• Adjusted EBITDA improved to $6.7 million from $0.9 million in Q2 2023
• Merger agreement with ANI Pharmaceuticals values Alimera's equity at approximately $320 million

Negative

• Net loss of $(3.3) million, although improved from $(10.7) million in Q2 2023
• Operating expenses increased to $23.2 million from $16.3 million in Q2 2023
• Cash and cash equivalents decreased to $10.8 million from $14.3 million at the end of Q1 2024

Insights

Financial Analyst

Alimera Sciences' Q2 2024 results show significant growth, with net revenue up 54% to $27 million. The key drivers were the integration of YUTIQ in the U.S. and increased international sales. U.S. revenue grew 48% to $17.6 million, while international revenue surged 65% to $9.4 million. The company's net loss improved from $(10.7) million to $(3.3) million and Adjusted EBITDA increased significantly from $0.9 million to $6.7 million. However, operating expenses rose due to merger-related costs and expanded commercial infrastructure. The pending acquisition by ANI Pharmaceuticals at $5.50 per share plus a potential $0.50 CVR values Alimera at approximately $320 million, indicating strong market confidence in the company's prospects.

Market Research Analyst

Alimera's Q2 results demonstrate robust market penetration and demand growth. Global end-user demand increased 6% year-over-year, with both U.S. and international markets showing identical growth rates. This consistent growth across markets suggests a strong product-market fit and effective global strategy. The acquisition of YUTIQ has significantly boosted U.S. revenues, indicating successful product integration and cross-selling opportunities. The modified royalty agreement with SWK Funding, reducing payments to 3.125% of net revenues for FAc-containing products, should improve long-term profitability. The pending ANI acquisition could provide Alimera with additional resources to further expand market share in the retinal health sector, potentially accelerating growth in the coming years.

Legal Expert

The merger agreement with ANI Pharmaceuticals is a significant legal development for Alimera. The all-cash transaction with a contingent value right (CVR) structure provides immediate value to shareholders while offering potential upside based on future performance. This deal structure mitigates some risk for ANI while incentivizing Alimera's continued growth. The merger's approval by both companies' boards is a positive sign, but regulatory approvals and shareholder votes are still pending. The modified royalty agreement with SWK Funding is another important legal development, potentially improving Alimera's financial position post-merger. Investors should note that the $2.2 million in merger-related expenses impacted this quarter's results and further costs may be incurred until the deal closes, expected later this year.

• Net Revenue up 54% to $27 Million vs. Q2 2023
• Global End User Demand up 6% vs. Q2 2023
• Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc.
  

ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. (“ANI”).

“We are pleased with our strong second quarter results, in line with our expectations, as we completed the integration of YUTIQ into our U.S. business and delivered $50 million in revenue in the first half this year," said Rick Eiswirth, Alimera’s President and Chief Executive Officer. "Further, we believe the acquisition agreement entered into with ANI Pharmaceuticals late in the second quarter is a testament to the value we have created at Alimera, and we look forward to completing the transaction later this quarter."

Key Second Quarter Financial Highlights:

• Net revenue of $27.0 million, up 54% vs. Q2 2023
• Net loss improved to $(3.3) million vs. $(10.7) million in Q2 2023
• Adjusted EBITDA of $6.7 million vs. $0.9 million in Q2 2023
• U.S. net revenue of $17.6 million, up 48% vs. $11.9 million in Q2 2023
• International net revenue of $9.4 million, up 65% vs. $5.7 million in Q2 2023
• Global end user demand of 3,821 units up 6% vs. Q2 2023 on a pro-forma basis

Second Quarter Corporate Highlights:

• On June 21, 2024, Alimera entered into an agreement and plan of merger with ANI. Under the proposed merger, Alimera will be acquired for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera’s equity at approximately $320 million in up front consideration, was approved by the ANI and Alimera Boards of Directors and is expected to close later this year.
• Modified the terms associated with royalty payments Alimera is obligated to pay SWK Funding LLC (“SWK”), reducing the royalty to 3.125% of net revenues, and defining any product containing fluocinolone acetonide (“FAc”) as being subject to such royalty, including ILUVIEN and YUTIQ.

Second Quarter 2024 Financial Results

Net Revenue
Consolidated global net revenue was up 54% to approximately $27 million for Q2 2024, compared to $17.5 million for Q2 2023, driven by the addition of YUTIQ in the U.S. segment, as well as increased sales volumes in the International segment of the business.

U.S. net revenue increased 48% to approximately $17.6 million for Q2 2024 compared to U.S. net revenue of $11.9 million for Q2 2023. The increase was primarily driven by net revenue from YUTIQ, which Alimera acquired in May 2023. U.S. end user demand grew by 6% in Q2 2024 to 2,189 units vs Q2 2023 on a pro-forma basis.

International net revenue increased 65% to approximately $9.4 million in Q2 2024, compared to approximately $5.7 million in Q2 2023. The increase in international net revenue in Q2 2024 was driven both by increased stocking of our international distributors and growth in end user demand. International end user demand grew 6% in Q2 2024 to 1,632 units vs Q2 2023.

Operating Expenses

Total operating expenses were approximately $23.2 million for Q2 2024, compared to approximately $16.3 million for Q2 2023. The increase was primarily attributable to $2.2 million in general and administrative expenses related to the merger agreement with ANI Pharmaceuticals, Inc., $1.8 million of additional sales and marketing expenses driven by expansion of our commercial infrastructure to support selling two products in the U.S., $1.2 million in additional amortization expense attributable to the YUTIQ acquisition in May 2023, and $1.2 million in additional stock-based compensation expense.

Cash and Cash Equivalents

As of June 30, 2024, Alimera had cash and cash equivalents of approximately $10.8 million, compared to $14.3 million at March 31, 2024 and $12.1 million at December 31, 2023. During the second quarter of 2024, the Company made $1.9 million of accrued licensor payments to EyePoint Pharmaceuticals, Inc. related to the acquisition of YUTIQ in May 2023, and $2.4 million of accrued exit fee payments as required by the Company’s existing loan agreements with SLR Capital Partners, LLC due to the achievement of certain revenue milestones.

About Alimera Sciences, Inc.

Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

Non-GAAP Financial Measures
This press release presents Adjusted EBITDA, as defined below, which is a non-GAAP financial measure. Alimera uses this measure to supplement the financial information presented on a GAAP basis. Alimera believes that excluding certain items from its GAAP financial results allows management to better understand its ongoing operations and analyze its financial performance from period to period and provides meaningful supplemental information to its investors.

Alimera defines “Adjusted EBITDA” as earnings before interest, taxes, depreciation, amortization, stock-based compensation expenses, net unrealized gains and losses from foreign currency exchange transactions, gains on extinguishment of debt, preferred stock dividends, severance expenses, expenses incurred with Merger Agreement, and change in fair value of warrant asset.

Alimera believes that Adjusted EBITDA, when taken together with its corresponding GAAP financial measure, provides meaningful supplemental information to its investors regarding its performance by excluding certain items that may not be indicative of its business, results of operations or outlook. Accordingly, Adjusted EBITDA for the three months ended June 30, 2024, and 2023, together with a reconciliation to GAAP net income or loss, its most directly comparable GAAP financial measure, has been presented in the table entitled “Reconciliation of GAAP Loss to Non-GAAP Adjusted EBITDA.”

This non-GAAP financial measure may not be comparable to similarly titled measures reported by other companies, including companies in Alimera’s industry, because not all companies calculate Adjusted EBITDA in an identical manner or may use other financial measures to evaluate their performance. Therefore, this non-GAAP financial measure may be limited in usefulness for comparison between companies.

The presentation of this non-GAAP financial measure is not intended to be considered in isolation from or as a substitute for other financial performance measures prepared in accordance with GAAP and should be read only in conjunction with financial information presented on a GAAP basis. The principal limitation of this non-GAAP financial measure is that it excludes significant elements required by GAAP to be recorded in Alimera’s financial statements. In addition, this non-GAAP financial measure is subject to inherent limitations because it reflects the exercise of judgment by management. Investors are encouraged not to rely on any single financial measure to evaluate Alimera’s business.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, Alimera’s expectations with respect to growth opportunities, demand for its product, its business strategy, future operations, future financial position including the timeline for achieving positive Adjusted EBITDA, future revenues, projected costs, prospects, plans and objectives. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “contemplates,” “predict,” “project,” “target,” “likely,” “potential,” “continue,” “ongoing,” “will,” “would,” “should,” “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based on current expectations and involve inherent risks and uncertainties (some of which are beyond Alimera’s control), including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s most recently filed Annual Report on Form 10-K, most recently filed Quarterly Report on Form 10-Q, and any of Alimera’s subsequent filings with the U.S. Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely on the forward-looking statements Alimera makes or that are made on its behalf as predictions of future events. These forward-looking statements speak only as of the date of this press release. Alimera undertakes no obligation to publicly update or revise any of the forward-looking statements made in this press release, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Additional Information and Where to Find It

In connection with the Merger, Alimera has filed a preliminary proxy statement and intends to file a definitive proxy statement. The definitive proxy statement and proxy card will be delivered to Alimera’s stockholders in advance of the special meeting relating to the proposed acquisition. Each of ANI and Alimera also plan to file other relevant materials with the SEC in connection with the Merger. INVESTORS IN AND SECURITY HOLDERS OF ALIMERA ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE, AS WELL AS ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR FURNISHED OR WILL BE FILED OR WILL BE FURNISHED BY EACH OF ANI AND ALIMERA WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE MERGER, RELATED MATTERS AND THE PARTIES TO THE MERGER. Materials filed by ANI and Alimera can be obtained free of charge at the SEC’s website, www.sec.gov. In addition, materials filed by ANI can be obtained free of charge at ANI’s website, www.anipharmaceuticals.com, and materials filed by Alimera can be obtained free of charge at Alimera’s website, www.alimerasciences.com.

For investor inquiries:  Scott Gordon  for Alimera Sciences  scottg@coreir.com	For media inquiries: Jules Abraham for Alimera Sciences julesa@coreir.com

ALIMERA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
		June 30,				December 31,
		2024				2023
		(In thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents		$	10,828			$	12,058
Restricted cash			33				32
Accounts receivable, net			37,079				34,545
Prepaid expenses and other current assets			4,013				3,909
Inventory			3,455				1,879
Total current assets			55,408				52,423
Property and equipment, net			2,278				2,466
Right-of-use assets, net			996				1,124
Intangible assets, net			91,587				97,355
Deferred tax asset			101				104
Warrant asset			7				52
Total assets		$	150,377			$	153,524
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	10,208			$	8,252
Accrued expenses			5,708				6,192
Accrued licensor payment			3,677				7,275
Finance lease obligations			245				194
Total current liabilities			19,838				21,913
Non-current liabilities:
Notes payable, net of discount			69,731				64,489
Accrued licensor payments			16,111				15,136
Other non-current liabilities			5,909				5,816
Total liabilities			111,589				107,354
Stockholders’ equity:
Preferred stock, $.01 par value — 10,000,000 shares authorized at June 30, 2024 and December 31, 2023, none issued			—				—
Common stock, $.01 par value — 150,000,000 shares authorized, 52,387,763 shares issued and outstanding at June 30, 2024 and 52,354,450 shares issued and outstanding at December 31, 2023			524				524
Common stock warrants			4,396				4,396
Additional paid-in capital			464,825				462,446
Accumulated deficit			(428,052	)			(418,490	)
Accumulated other comprehensive loss			(2,905	)			(2,706	)
Total stockholders’ equity			38,788				46,170
Total liabilities and stockholders’ equity		$	150,377			$	153,524

ALIMERA SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
		(In thousands, except share and per share data)
Net revenue		$	27,000			$	17,538			$	50,011			$	31,084
Cost of goods sold, excluding depreciation and amortization			(3,831	)			(2,425	)			(7,184	)			(4,453	)
Gross profit			23,169				15,113				42,827				26,631
Operating expenses:
Research, development and medical affairs expenses			4,263				3,648				8,624				7,812
General and administrative expenses			7,379				4,373				12,811				8,544
Sales and marketing expenses			8,511				6,434				17,593				12,238
Depreciation and amortization			3,093				1,866				6,178				2,547
Total operating expenses			23,246				16,321				45,206				31,141
Loss from operations			(77	)			(1,208	)			(2,379	)			(4,510	)
Interest expense and other, net			(3,153	)			(1,694	)			(6,892	)			(3,361	)
Unrealized foreign currency loss, net			(125	)			(7	)			(321	)			(20	)
Loss on extinguishment of debt			—				(1,079	)			—				(1,079	)
Change in fair value of common stock warrant			—				(105	)			—				(91	)
Change in fair value of warrant asset			1				(5,911	)			(45	)			(5,911	)
Net loss before income taxes			(3,354	)			(10,004	)			(9,637	)			(14,972	)
Income tax benefit (provision)			43				(25	)			75				(25	)
Net loss			(3,311	)			(10,029	)			(9,562	)			(14,997	)
Preferred stock dividends			—				(669	)			—				(683	)
Net loss applicable to common stockholders		$	(3,311	)		$	(10,698	)		$	(9,562	)		$	(15,680	)
Net loss per share — basic and diluted		$	(0.06	)		$	(1.32	)		$	(0.18	)		$	(2.07	)
Weighted average shares outstanding — basic and diluted			54,383,604				8,093,640				54,370,216				7,565,868

ALIMERA SCIENCES, INC. RECONCILIATION OF U.S. GAAP NET LOSS TO NON-GAAP ADJUSTED EBITDA (UNAUDITED)
		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2024				2023				2024				2023
		(In thousands)
U.S. GAAP net loss		$	(3,311	)		$	(10,029	)		$	(9,562	)		$	(14,997	)
Adjustments to U.S. GAAP net loss:
Interest expense and other, net			3,153				1,694				6,892				3,361
Expenses incurred with Merger Agreement			2,226				—				2,226				—
Income tax (benefit) provision			(43	)			25				(75	)			25
Depreciation and amortization			3,093				1,866				6,178				2,547
Stock-based compensation			1,457				217				2,302				442
Foreign currency exchange losses			125				7				321				20
Extinguishment of debt			—				1,079				—				1,079
Change in fair value of warrant asset			(1	)			5,911				45				5,911
Change in fair value of common stock warrant			—				105				—				91
Severance expenses			15				—				191				—
Non-GAAP adjusted EBITDA		$	6,714			$	875			$	8,518			$	(1,521	)

FAQ

What was Alimera Sciences' (ALIM) net revenue for Q2 2024?

Alimera Sciences reported net revenue of $27 million for Q2 2024, a 54% increase compared to Q2 2023.

How much did Alimera's (ALIM) U.S. net revenue grow in Q2 2024?

Alimera's U.S. net revenue grew 48% to $17.6 million in Q2 2024 compared to Q2 2023.

What was Alimera Sciences' (ALIM) global end user demand in Q2 2024?

Alimera Sciences reported global end user demand of 3,821 units in Q2 2024, up 6% compared to Q2 2023 on a pro-forma basis.

What is the value of Alimera Sciences' (ALIM) merger agreement with ANI Pharmaceuticals?

The merger agreement values Alimera's equity at approximately $320 million in upfront consideration, with $5.50 per share in cash at closing and a potential additional $0.50 per share through a contingent value right.